Optimer Pharmaceuticals, Inc. (OPTR-NASDAQ)

“The vision for Optimer Pharmaceuticals currently is to be a biopharmaceutical company that discovers, develops and commercializes innovative anti-infective products. Our current products address the treatment of gastro-intestinal infections and related diseases. Other products in our pipeline that are not in that space, we want to develop to a stage where we can then opportunistically partner out. With our recent announcement of buying back or regaining the North American rights to our lead product candidate, Difimicin (OPT-80) from Par Pharmaceutical Companies, Inc. (NYSE: PRX), we now hold worldwide rights to Difimicin. Therefore, we are on track and the last phase of what we want to be as a company is commercialization. This gives us an opportunity to put a sales force in place in the United States and have two products in their hands, Difimicin and Prulifloxacin (OPT-99), which is an antibiotic currently in a Phase 3 trial for the treatment of travelers’ diarrhea.” - John D. Prunty, C.P.A.